Multiple Sclerosis Journal

Article	Citations
Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition	959
COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by February 2021	177
Exercise and lifestyle physical activity recommendations for people with multiple sclerosis throughout the disease course	150
A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis	70
COVID-19 in multiple sclerosis: The Dutch experience	70
Multiple sclerosis management during the COVID-19 pandemic	60
A smartphone sensor-based digital outcome assessment of multiple sclerosis	51
Neurofilament levels are associated with blood–brain barrier integrity, lymphocyte extravasation, and risk factors following the first demyelinating event in multiple sclerosis	50
COVID-19 in people with multiple sclerosis: A global data sharing initiative	48
Vaccinations in patients with multiple sclerosis: A Delphi consensus statement	39
MSVirtual 2020 – Poster Abstracts	38
Aggressive multiple sclerosis (1): Towards a definition of the phenotype	38
In vivo imaging of chronic active lesions in multiple sclerosis	37
Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study	36
Synaptic and complement markers in extracellular vesicles in multiple sclerosis	36
Progressive multifocal leukoencephalopathy in dimethyl fumarate-treated multiple sclerosis patients	36
Effectiveness and safety of cladribine in MS: Real-world experience from two tertiary centres	36
Macular ganglion cell–inner plexiform layer thinning as a biomarker of disability progression in relapsing multiple sclerosis	35
Alemtuzumab in multiple sclerosis during the COVID-19 pandemic: A mild uncomplicated infection despite intense immunosuppression	35
Early treatment delays long-term disability accrual in RRMS: Results from the BMSD network	34
Fatigue, depression, and pain in multiple sclerosis: How neuroinflammation translates into dysfunctional reward processing and anhedonic symptoms	34
Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension	33
The relative contributions of obesity, vitamin D, leptin, and adiponectin to multiple sclerosis risk: A Mendelian randomization mediation analysis	32
Fatigue, sleep disorders, anaemia and pain in the multiple sclerosis prodrome	32
Recovery from COVID-19 in a B-cell-depleted multiple sclerosis patient	31

Wearable technologies to measure clinical outcomes in multiple sclerosis: A scoping review	30
Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: Analysis of aquaporin-4–immunoglobulin G–seropositive participants taking inebilizumab for ⩾4 years in the N-MO	30
MOG-IgG1 and co-existence of neuronal autoantibodies	30
Real-world keystroke dynamics are a potentially valid biomarker for clinical disability in multiple sclerosis	29
Childhood obesity and multiple sclerosis: A Mendelian randomization study	29
Which exercise and behavioural interventions show most promise for treating fatigue in multiple sclerosis? A network meta-analysis	29
Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapies	29
A randomized study of natalizumab dosing regimens for relapsing–remitting multiple sclerosis	28
Neurofilament light chain in a phase 2 clinical trial of ibudilast in progressive multiple sclerosis	28
Expansion of chronic lesions is linked to disease progression in relapsing–remitting multiple sclerosis patients	28
The emerging role of artificial intelligence in multiple sclerosis imaging	28
Exercise training and cognitive performance in persons with multiple sclerosis: A systematic review and multilevel meta-analysis of clinical trials	27
Long-term safety and efficacy of dimethyl fumarate for up to 13 years in patients with relapsing-remitting multiple sclerosis: Final ENDORSE study results	27
ADEM after ChAdOx1 nCoV-19 vaccine: A case report	27
COVID-19 pneumonia in a multiple sclerosis patient with severe lymphopenia due to recent cladribine treatment	27
Age-related adverse events of disease-modifying treatments for multiple sclerosis: A meta-regression	27
COVID-19 in patients with multiple sclerosis undergoing disease-modifying treatments	26
Dimethyl fumarate treatment shifts the immune environment toward an anti-inflammatory cell profile while maintaining protective humoral immunity	26
Cognitive impairment, the central vein sign, and paramagnetic rim lesions in RIS	26
Personalized B-cell tailored dosing of ocrelizumab in patients with multiple sclerosis during the COVID-19 pandemic	25
A validation study for remote testing of cognitive function in multiple sclerosis	25
Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II	25
Characterisation of MS phenotypes across the age span using a novel data set integrating 34 clinical trials (NO.MS cohort): Age is a key contributor to presentation	25
SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study	25
Coexisting systemic and organ-specific autoimmunity in MOG-IgG1-associated disorders versus AQP4-IgG+ NMOSD	25
Humoral immune response after COVID-19 in multiple sclerosis: A nation-wide Austrian study	24
Impact of COVID-19 on multiple sclerosis care and management: Results from the European Committee for Treatment and Research in Multiple Sclerosis survey	24
Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study	24
Cortical lesion hotspots and association of subpial lesions with disability in multiple sclerosis	24
Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years	24
Defective CD19+CD24hiCD38hi transitional B-cell function in patients with relapsing-remitting MS	24
High-intensity interval training reduces neutrophil-to-lymphocyte ratio in persons with multiple sclerosis during inpatient rehabilitation	24
Keeping standards of multiple sclerosis care through the COVID-19 pandemic	23
Autologous haematopoietic stem cell transplantation as a first-line disease-modifying therapy in patients with ‘aggressive’ multiple sclerosis	23
Interpreting change on the Symbol Digit Modalities Test in people with relapsing multiple sclerosis using the reliable change methodology	23
The risk of infection in patients with multiple sclerosis treated with disease-modifying therapies: A Delphi consensus statement	23
Contrasting the brain imaging features of MOG-antibody disease, with AQP4-antibody NMOSD and multiple sclerosis	23
Increased rate of hospitalisation for COVID-19 among rituximab-treated multiple sclerosis patients: A study of the Swedish multiple sclerosis registry	22
Acute disseminated encephalomyelitis in children and adults: A focused review emphasizing new developments	22
Real-world effectiveness of cladribine for Australian patients with multiple sclerosis: An MSBase registry substudy	22
Optical coherence tomography angiography indicates subclinical retinal disease in neuromyelitis optica spectrum disorders	22
Adverse event profile differences between rituximab and ocrelizumab: Findings from the FDA Adverse Event Reporting Database	21
Serum neurofilament light in MS: The first true blood-based biomarker?	21
Association of body mass index with longitudinal rates of retinal atrophy in multiple sclerosis	21
Paradigm shifts: Early initiation of high-efficacy disease-modifying treatment in multiple sclerosis	21
ECTRIMS 2021 – ePoster	21
Frailty in ageing persons with multiple sclerosis	21
Optic chiasm involvement in AQP-4 antibody–positive NMO and MOG antibody–associated disorder	21
COVID-19 associated with encephalomyeloradiculitis and positive anti-aquaporin-4 antibodies: Cause or coincidence?	21
Aggressive multiple sclerosis (2): Treatment	21

Relationship between paramagnetic rim lesions and slowly expanding lesions in multiple sclerosis	21
Temporal profile of serum neurofilament light in multiple sclerosis: Implications for patient monitoring	21
Deep learning segmentation of gadolinium-enhancing lesions in multiple sclerosis	21
Serum ceramide levels are altered in multiple sclerosis	21
A novel in-home digital treatment to improve processing speed in people with multiple sclerosis: A pilot study	20
The frequency and characteristics of MS misdiagnosis in patients referred to the multiple sclerosis centre of Catalonia	20
Switching to ocrelizumab in RRMS patients at risk of PML previously treated with extended interval dosing of natalizumab	20
ACTRIMS Forum 2023 - Poster Presentations	20
Time matters: Early-phase multiple sclerosis is accompanied by considerable impairments across multiple domains	20
Feelings of depression, pain and walking difficulties have the largest impact on the quality of life of people with multiple sclerosis, irrespective of clinical phenotype	20
Disability in multiple sclerosis is related to thalamic connectivity and cortical network atrophy	20
The cerebellum and its network: Disrupted static and dynamic functional connectivity patterns and cognitive impairment in multiple sclerosis	20
Cerebrospinal fluid kappa free light chains for the diagnosis of multiple sclerosis: A systematic review and meta-analysis	19
Household paired design reduces variance and increases power in multi-city gut microbiome study in multiple sclerosis	19
Serum neurofilament light-chain levels in children with monophasic myelin oligodendrocyte glycoprotein-associated disease, multiple sclerosis, and other acquired demyelinating syndrome	19
Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors	19
Structural constraints of functional connectivity drive cognitive impairment in the early stages of multiple sclerosis	19
Mediterranean diet is linked to less objective disability in multiple sclerosis	19
Gut commensals, dysbiosis, and immune response imbalance in the pathogenesis of multiple sclerosis	19
Classifying multiple sclerosis patients on the basis of SDMT performance using machine learning	19
De-escalating rituximab dose results in stability of clinical, radiological, and serum neurofilament levels in multiple sclerosis	18
Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years	18
MOG-antibody-associated longitudinal extensive myelitis after ChAdOx1 nCoV-19 vaccination	18
COVID-19 vaccine hesitancy in multiple sclerosis: A cross-sectional survey	18
Atlas of MS 2020: Informing global policy change	18
Mapping white matter damage distribution in neuromyelitis optica spectrum disorders with a multimodal MRI approach	17
Sustained reduction of serum neurofilament light chain over 7 years by alemtuzumab in early relapsing–remitting MS	17
Quantifying cognition and fatigue to enhance the sensitivity of the EDSS during relapses	17
Efficacy of high-intensity aerobic exercise on cognitive performance in people with multiple sclerosis: A randomized controlled trial	17
Patient-reported financial toxicity in multiple sclerosis: Predictors and association with care non-adherence	17
The timed 25-foot walk in a large cohort of multiple sclerosis patients	17
Rituximab in patients with pediatric multiple sclerosis and other demyelinating disorders of the CNS: Practical considerations	17
Performance validity in outpatients with multiple sclerosis and cognitive complaints	17
Vascular comorbidity is associated with lower brain volumes and lower neuroperformance in a large multiple sclerosis cohort	17
Pregnancy outcome following first-trimester exposure to fingolimod: A collaborative ENTIS study	16
Cladribine transfer into human milk: A case report	16
The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focuse	16
Occurrence and microstructural features of slowly expanding lesions on fingolimod or natalizumab treatment in multiple sclerosis	16
Evidence of subclinical quantitative retinal layer abnormalities in AQP4-IgG seropositive NMOSD	16
The central vein sign in multiple sclerosis patients with vascular comorbidities	16
Paramagnetic rims are a promising diagnostic imaging biomarker in multiple sclerosis	16
Central vein sign and other radiographic features distinguishing myelin oligodendrocyte glycoprotein antibody disease from multiple sclerosis and aquaporin-4 antibody-positive neuromyelitis optica	16
Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial	16
Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: The CLARITY and CLARITY Extension studies	15
Staging and stratifying cognitive dysfunction in multiple sclerosis	15
Current status of neuroprotective and neuroregenerative strategies in multiple sclerosis: A systematic review	15
Real-world disability improvement in patients with relapsing–remitting multiple sclerosis treated with natalizumab in the Tysabri Observational Program	15
Investigating the potential disease-modifying and neuroprotective efficacy of exercise therapy early in the disease course of multiple sclerosis: The Early Multiple Sclerosis Exercise Study (EMSES)	15
Increased functional sensorimotor network efficiency relates to disability in multiple sclerosis	15
Home-based Pilates for symptoms of anxiety, depression and fatigue among persons with multiple sclerosis: An 8-week randomized controlled trial	15
Reliability, construct and concurrent validity of a smartphone-based cognition test in multiple sclerosis	15
Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analys	15
Longitudinal follow-up of serum biomarkers in patients with neuromyelitis optica spectrum disorder	15
Sensitivity of T1/T2-weighted ratio in detection of cortical demyelination is similar to magnetization transfer ratio using post-mortem MRI	15
Prevalence, co-occurrence, and trajectories of pain, fatigue, depression, and anxiety in the year following multiple sclerosis diagnosis	15
School performance, psychiatric comorbidity, and healthcare utilization in pediatric multiple sclerosis: A nationwide population-based observational study	14
Serum neurofilament light chain concentration predicts disease worsening in multiple sclerosis	14
Leptomeningeal enhancement on post-contrast FLAIR images for early diagnosis of Susac syndrome	14
Durability of no evidence of disease activity-3 (NEDA-3) in patients receiving cladribine tablets: The CLARITY extension study	14
What does first-line therapy mean for paediatric multiple sclerosis in the current era?	14
Characterization of thalamic lesions and their correlates in multiple sclerosis by ultra-high-field MRI	14
Operationalization of a frailty index in patients with multiple sclerosis: A cross-sectional investigation	14
Extended dosing of monoclonal antibodies in multiple sclerosis	14
Acute and chronic synaptic pathology in multiple sclerosis gray matter	14
Alemtuzumab: Rare serious adverse events of a high-efficacy drug	14
Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trial	14
Accurate classification of secondary progression in multiple sclerosis using a decision tree	13
Safety of COVID-19 vaccines in multiple sclerosis: A systematic review and meta-analysis	13
The SDMT is not information processing speed	13
Effectiveness of the transcutaneous tibial nerve stimulation and pelvic floor muscle training with biofeedback in women with multiple sclerosis for the management of overactive bladder	13
CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis	13
Cerebrospinal fluid kappa free light chains for the diagnosis of multiple sclerosis: A consensus statement	13
Longitudinal clinical study of patients with iron rim lesions in multiple sclerosis	13
Effect of applying inclusion and exclusion criteria of phase III clinical trials to multiple sclerosis patients in routine clinical care	13
Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions	13
Ethical use of off-label disease-modifying therapies for multiple sclerosis	13
The frequency and characteristics of multiple sclerosis misdiagnosis in Latin America: A referral center study in Buenos Aires, Argentina	13
Switching from natalizumab to ocrelizumab in patients with multiple sclerosis	13
Preserved T cell responses to SARS-CoV-2 in anti-CD20 treated multiple sclerosis	13
ECTRIMS 2022 – Poster	13

Resting-state functional connectivity of anterior and posterior cerebellar lobes is altered in multiple sclerosis	13
Cortical axonal loss is associated with both gray matter demyelination and white matter tract pathology in progressive multiple sclerosis: Evidence from a combined MRI-histopathology study	13
Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data	13
Incidence and clinical outcome of Coronavirus disease 2019 in a cohort of 11,560 Brazilian patients with multiple sclerosis	13
Lesion-level correspondence and longitudinal properties of paramagnetic rim and slowly expanding lesions in multiple sclerosis	13
Anxiety and depression affect performance on the symbol digit modalities test over time in MS and other immune disorders	13
Functional brain network organization measured with magnetoencephalography predicts cognitive decline in multiple sclerosis	13
Paramagnetic rim lesions are associated with pathogenic CSF profiles and worse clinical status in multiple sclerosis: A retrospective cross-sectional study	13
Switch from sequestering to anti-CD20 depleting treatment: disease activity outcomes during wash-out and in the first 6 months of ocrelizumab therapy	12
Identification of regulatory T cell molecules associated with severity of multiple sclerosis	12
Body mass index as a predictor of MS activity and progression among participants in BENEFIT	12
Is humoral and cellular response to SARS-CoV-2 vaccine modified by DMT in patients with multiple sclerosis and other autoimmune diseases?	12
Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis	12
MRI correlates of clinical disability and hand-motor performance in multiple sclerosis phenotypes	12
Measurement of white matter fiber-bundle cross-section in multiple sclerosis using diffusion-weighted imaging	12
Pregnancy in multiple sclerosis women with relapses in the year before conception increases the risk of long-term disability worsening	12
Methylome and transcriptome signature of bronchoalveolar cells from multiple sclerosis patients in relation to smoking	12
ECTRIMS 2022 – ePoster	12
Brain structural and functional alterations in MOG antibody disease	12
Cerebrospinal fluid inflammatory profile of cognitive impairment in newly diagnosed multiple sclerosis patients	12
Plasma glial fibrillary acidic protein and neurofilament light chain in relation to disability worsening in multiple sclerosis	12
Optical coherence tomography outcomes from SPRINT-MS, a multicenter, randomized, double-blind trial of ibudilast in progressive multiple sclerosis	12
Emergency medical care for multiple sclerosis: A five-year population study in the Campania Region (South Italy)	11
Predictive value of optical coherence tomography, multifocal visual evoked potentials, and full-field visual evoked potentials of the fellow, non-symptomatic eye for subsequent multiple sclerosis deve	11
Mental health of people with multiple sclerosis during the COVID-19 outbreak: A prospective cohort and cross-sectional case–control study of the UK MS Register	11
Multiple sclerosis diagnosis: Knowledge gaps and opportunities for educational intervention in neurologists in the United States	11
Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSD	11
Serum MOG-IgG in children meeting multiple sclerosis diagnostic criteria	11
Youth with multiple sclerosis have low levels of fitness	11
Serum contactin-1 as a biomarker of long-term disease progression in natalizumab-treated multiple sclerosis	11
Artificial double inversion recovery images for (juxta)cortical lesion visualization in multiple sclerosis	11
The effects of supervised versus home Pilates-based core stability training on lower extremity muscle strength and postural sway in people with multiple sclerosis	11
Productivity loss among people with early multiple sclerosis: A Canadian study	11
Cumulative effects of therapies on disability in relapsing multiple sclerosis	11
Mendelian randomization provides no evidence for a causal role in the bidirectional relationship between depression and multiple sclerosis	11
Inhibitory synaptic loss drives network changes in multiple sclerosis: An ex vivo to in silico translational study	11
Changes in multiple sclerosis symptoms are associated with changes in work productivity of people living with multiple sclerosis	11
Conscientiousness and deterioration in employment status in multiple sclerosis over 3 years	11
Effect of ofatumumab versus placebo in relapsing multiple sclerosis patients from Japan and Russia: Phase 2 APOLITOS study	11
PRF1 mutation alters immune system activation, inflammation, and risk of autoimmunity	11
Prioritizing progressive MS rehabilitation research: A call from the International Progressive MS Alliance	11
Hypertension and hypertension severity in Hispanics/Latinx with MS	10
Serum neurofilament light and MRI predictors of cognitive decline in patients with secondary progressive multiple sclerosis: Analysis from the MS-STAT randomised controlled trial	10
Longitudinal analysis of T1w/T2w ratio in patients with multiple sclerosis from first clinical presentation	10
Patient reported outcomes and performance metrics at diagnosis of secondary progressive multiple sclerosis	10
Ocrelizumab reduces thalamic volume loss in patients with RMS and PPMS	10
Clinical perspective on pain in multiple sclerosis	10
Anti-CD20 therapy corrects a CD8 regulatory T cell deficit in multiple sclerosis	10
EDSS 0 is not normal: Multiple sclerosis disease burden below the clinical threshold	10
Slowly expanding lesions are a marker of progressive MS – Yes	10
Pregnancy and multiple sclerosis: 2022 recommendations from the French multiple sclerosis society	10
Alemtuzumab treatment in Denmark: A national study based on the Danish Multiple Sclerosis Registry	10
MS, pregnancy and COVID-19	10
Characterization of multiple sclerosis neuroinflammation and neurodegeneration with relaxation and diffusion basis spectrum imaging	10
Exploring CSF neurofilament light as a biomarker for MS in clinical practice; a retrospective registry-based study	10
Exposure to natalizumab during pregnancy and lactation is safe – Yes	10
T1/T2-weighted ratio is a surrogate marker of demyelination in multiple sclerosis: No	9
Pro-inflammatory adiponectin in pediatric-onset multiple sclerosis	9
Cardiorespiratory fitness and free-living physical activity are not associated with cognition in persons with progressive multiple sclerosis: Baseline analyses from the CogEx study	9
Slowly expanding lesions are a marker of progressive MS – No	9
Comparison of MOG and AQP4 antibody seroprevalence in Korean adults with inflammatory demyelinating CNS diseases	9
High Prudent diet factor score predicts lower relapse hazard in early multiple sclerosis	9
CSF chitinase 3-like 1 is associated with iron rims in patients with a first demyelinating event	9
Exercise and the brain in multiple sclerosis	9
An electronic, unsupervised patient-reported Expanded Disability Status Scale for multiple sclerosis	9
Physical exercise in multiple sclerosis is not just a symptomatic therapy: It has a disease-modifying effect—Yes	9
Altered brain network function during attention-modulated visual processing in multiple sclerosis	9
Pathways to cures for multiple sclerosis: A research roadmap	9
Pregnancy in women with multiple sclerosis in France from 2010 to 2015: Incidence, outcomes, and exposure to disease-modifying therapies	9
Epilepsy as a predictor of disease progression in multiple sclerosis	9
A proposed new taxonomy of cognitive phenotypes in multiple sclerosis: The International Classification of Cognitive Disorders in MS (IC-CoDiMS)	9
Brighter spotty lesions on spinal MRI help differentiate AQP4 antibody-positive NMOSD from MOGAD	9
Depression and cognitive function in early multiple sclerosis: Multitasking is more sensitive than traditional assessments	9
Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry	9
Multiple sclerosis: Is there a risk of worsening after yellow fever vaccination?	9
Post-vaccine COVID-19 in patients with multiple sclerosis or neuromyelitis optica	9
Multi-layer analysis of quantitative 7 T magnetic resonance imaging in the cortex of multiple sclerosis patients reveals pathology associated with disability	9
Long-term course and morphological MRI correlates of cognitive function in multiple sclerosis	9
Measurement of neurofilaments improves stratification of future disease activity in early multiple sclerosis	9
BEST-MS: A prospective head-to-head comparative study of natalizumab and fingolimod in active relapsing MS	9
Brain MRI activity during the year before pregnancy can predict post-partum clinical relapses	9
Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis	9
Visual field loss and structure–function relationships in optic neuritis associated with myelin oligodendrocyte glycoprotein antibody	9
Oral nomegestrol acetate and transdermal 17-beta-estradiol for preventing post-partum relapses in multiple sclerosis: The POPARTMUS study	8
Clinical predictors of driving simulator performance in drivers with multiple sclerosis	8
A possible case of serum sickness after ocrelizumab infusion	8
Depression and multiple sclerosis: A bidirectional Mendelian randomisation study	8
Evaluation of brain and spinal cord lesion distribution criteria at disease onset in distinguishing NMOSD from MS and MOG antibody-associated disorder	8
Progressive multifocal leukoencephalopathy on dimethyl fumarate with preserved lymphocyte count but deep T-cells exhaustion	8
Dietary factors in experimental autoimmune encephalomyelitis and multiple sclerosis: A comprehensive review	8
Effects of teriflunomide treatment on cognitive performance and brain volume in patients with relapsing multiple sclerosis: Post hoc analysis of the TEMSO core and extension studies	8
Menstrual cycle resumption and female fertility after autologous hematopoietic stem cell transplantation for multiple sclerosis	8
Oligoclonal IgM bands in the cerebrospinal fluid of patients with relapsing MS to inform long-term MS disability	8
COVID-19 will change MS care forever – No	8
Long-term clinical, MRI, and cognitive follow-up in a large cohort of pathologically confirmed, predominantly tumefactive multiple sclerosis	8